Breast cancer patients were grouped according to tumor feature, invasive and noninvasive, hormone receptor status as Luminal A (Her2−, ER+, PR+/–), Luminal B (Her2+, ER+, PR+/−), Her2 overexpressed (Her2+, ER−, PR–), triple negative (Her2−, ER−, PR−) and, lastly, according to inflammatory breast cancer (IBC) −/+ Her2/Neu. This evidence concerns the gene ERBB2 and breast carcinoma.